Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

OTHER 2INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Plasma cell 1Lymphoid 1

Conditions

Multiple Myeloma 112Recurrence 34Neoplasms, Plasma Cell 10Neoplasms 9Lymphoma, Non-Hodgkin 4Hematologic Neoplasms 3Renal Insufficiency 2Primary Myelofibrosis 2Hematologic Diseases 2Waldenstrom Macroglobulinemia 1Sarcoma 1Prostatic Neoplasms 1Polycythemia Vera 1Plasmacytoma 1Neoplasms by Histologic Type 1Neoplasm Metastasis 1Medulloblastoma 1Malignant Plasma Cell Neoplasms 1Lymphoproliferative Disorders 1Lymphoma, T-Cell, Peripheral 1Lymphoma, Large B-Cell, Diffuse 1Lymphoma, Follicular 1Lymphoma, B-Cell 1Lymphoma 1Lymphatic Diseases 1Leukemia, Myeloid, Acute 1Leukemia, Megakaryoblastic, Acute 1Leukemia, Lymphocytic, Chronic, B-Cell 1Leukemia, B-Cell 1Leukemia 1

Interventions

zanubrutinib 9ibrutinib 9Rituximab 5idelalisib 4venetoclax 3pirtobrutinib 3ublituximab 2bazlitoran 2acalabrutinib 2Dexamethasone 2ARQ531 2umbralisib 1selinexor 1sapanisertib 1pomalidomide 1perifosine 1pembrolizumab 1ontuxizumab 1ofatumumab 1obinutuzumab 1mavorixafor 1loncastuximab tesirine 1fludarabine 1epratuzumab 1enzastaurin 1carfilzomib 1brexucabtagene autoleucel 1WW Domain-Containing Oxidoreductase 1Voriconazole 1Vitamin B 12 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
INDUSTRY × Waldenstrom Macroglobulinemia × pomalidomide × Clear all
NCT02071888 2018-07-18

Study of the Glutaminase Inhibitor CB-839 in Hematological Tumors

Calithera Biosciences, Inc

Phase 1 Completed
25 enrolled
LymphoidPlasma cell

Lymphoma, Non-Hodgkin, Waldenstrom Macroglobulinemia, Multiple Myeloma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡